Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2025-12-21 Regulatory Filings
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Positive Update on IMP761 Phase 1 2 pages 235.6KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing a positive update on a Phase I clinical study of IMP761, a LAG-3 agonist antibody for autoimmune diseases. It provides details on the study progress, safety, efficacy, and future plans for data presentation. There are no financial statements, regulatory filings, or detailed financial data. The content focuses on clinical trial progress and company product development updates, typical of a Capital/Financing Update or general corporate announcement. However, since it is about clinical trial progress and not fundraising or capital structure changes, it does not fit CAP. It is not a regulatory filing or earnings release. Given the nature of the announcement as a clinical trial update, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2025-12-21 English
TACTI-004 phase III trial enrolment continues at robust pace 2 pages 180.9KB
Capital/Financing Update Classification · 85% confidence The document is a press release announcing operational progress in a Phase III clinical trial (TACTI-004) by Immutep Limited. It provides updates on patient enrollment, regulatory approvals, and trial milestones but does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release or financial report but rather a corporate update on clinical trial progress and business development. The content fits best under Capital/Financing Update (CAP) as it relates to progress in a key clinical trial which is critical for the company's capital and financing outlook, but it is not a direct financing announcement. However, given the nature of the update focusing on operational progress and trial enrollment, it is best classified as a Capital/Financing Update (CAP) because it informs investors about progress that impacts company valuation and financing prospects. The document length is moderate and contains substantive operational information rather than just an announcement of a report, so it is not RPA or RNS.
2025-12-15 English
Immutep enters into Strategic Collaboration with Dr. Reddy's 3 pages 247.7KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic collaboration and licensing agreement between Immutep and Dr. Reddy's for the commercialization of a drug, Eftilagimod Alfa. It details the terms of the agreement, payments, and rights but does not contain financial statements, regulatory filings, or detailed financial performance data. It is not an earnings release, annual report, or any form of financial report. It is also not a regulatory filing or certification. The content is focused on a business collaboration and licensing deal, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through licensing agreements and milestone payments. The document length is sufficient and contains substantive information about the deal, not just an announcement of a report publication or voting results. Therefore, the most appropriate classification is CAP with high confidence.
2025-12-07 English
Application for quotation of securities - IMM 6 pages 19.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX announcement for the application for quotation of securities. It details the issuance and conversion of performance rights into ordinary shares, including specifics about the number of securities, issue dates, and whether the securities are held by key management personnel. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement related to the issuance and quotation of new shares on the ASX. This fits the category of Share Issue/Capital Change (SHA). The document length (6571 characters) and content confirm it is not merely a report publication announcement or a regulatory filing fallback. Therefore, the classification is SHA with high confidence.
2025-12-04 English
Change of Director's Interest Notice - L Boyce 3 pages 308.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including shares and performance rights acquired and disposed of. The document is a formal notification of insider share transactions by a director, consistent with regulatory requirements for disclosure of personal share dealings. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives.
2025-12-04 English
Change of Director's Interest Notice - P Meyers 3 pages 305.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities held by a director, including the number of shares and performance rights acquired, disposed, and held before and after the change. The document is a formal notification of a director's personal share transactions, specifically the acquisition of performance rights as remuneration. There is no financial performance data, earnings information, or management discussion. The content fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is 4343 characters, which is consistent with a detailed insider trading notice rather than a full report or announcement of a report.
2025-12-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.